Patent intelligence · US
US 11406713
Xanthine oxidase inhibitor formulations
Xanthine oxidase inhibitor formulations
Patent details — US 11406713
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 9, 2022
- Expiration
- Aug 4, 2042
- Applicant
- XORTX THERAPEUTICS, INC.
- Claims
- 11
- CPC classes
- A61K, A61K31/197, A61K31/198, A61K31/375
Quick answer
US 11406713 (Xanthine oxidase inhibitor formulations) is held by XORTX THERAPEUTICS, INC.. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- XORTX THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/197, A61K31/198, A61K31/375, A61K31/4188, A61K31/4415
Frequently asked questions
What is US patent 11406713?
US 11406713 (Xanthine oxidase inhibitor formulations) is held by XORTX THERAPEUTICS, INC.. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11406713?
XORTX THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 11406713 expire?
Our index shows an expiration date of Aug 4, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.